TC-MCH 7c is an oral, selectable and blood-brain barrier penetrating MCH1R antagonist with IC50 performance of 5.6 nM against hMCH1R, and TC-MCH 7c is a phenylpyridone derivative with MCH1R Ki of 3.4 nM against human. In mice, MCH1R Ki was 3.0 nM.

MCH1R (human):5.6 nM, MCH1R (human):3.4 nM (ki), MCH1R (mouse):3.0 nM, MCH1R (mouse):3.0 nM , MCH1R (human):(ki)3.4 nM , MCH1R (human):5.6 nM

在[Ca2+]i动员活动中，TC-MCH 7c对MCH1R的IC50为9.7 μM [1]。TC-MCH 7c对FLIPR的IC50为23 nM，而对hERG的IC50为9.0 μM [2]。

在DIO小鼠模型中，TC-MCH 7c（口服；3-30 mg/kg；每日一次，连续1.5个月）能够呈现出优异的剂量依赖性体重降低效果[1]。TC-MCH 7c（口服；3至30mg/kg）在2小时、15小时和24小时的浓度分别为5.1、1.8和0.7 μM[2]。